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Abstract
Introduction: Although approximately 25 common genetic susceptibility loci have been identified to be
independently associated with breast cancer risk through genome-wide association studies (GWAS), the genetic risk
variants reported to date only explain a small fraction of the heritability of breast cancer. Furthermore, GWAS-
identified loci were primarily identified in women of European descent.
Methods: To evaluate previously identified loci in Korean women and to identify additional novel breast cancer
susceptibility variants, we conducted a three-stage GWAS that included 6,322 cases and 5,897 controls.
Results: In the validation study using Stage I of the 2,273 cases and 2,052 controls, seven GWAS-identified loci
[5q11.2/MAP3K1 (rs889312 and rs16886165), 5p15.2/ROPN1L (rs1092913), 5q12/MRPS30 (rs7716600), 6q25.1/ESR1
(rs2046210 and rs3734802), 8q24.21 (rs1562430), 10q26.13/FGFR2 (rs10736303), and 16q12.1/TOX3 (rs4784227 and
rs3803662)] were significantly associated with breast cancer risk in Korean women (Ptrend < 0.05). To identify
additional genetic risk variants, we selected the most promising 17 SNPs in Stage I and replicated these SNPs in
2,052 cases and 2,169 controls (Stage II). Four SNPs were further evaluated in 1,997 cases and 1,676 controls (Stage
III). SNP rs13393577 at chromosome 2q34, located in the Epidermal Growth Factor Receptor 4 (ERBB4) gene, showed
a consistent association with breast cancer risk with combined odds ratios (95% CI) of 1.53 (1.37-1.70) (combined P
for trend = 8.8 × 10-14).
Conclusions: This study shows that seven breast cancer susceptibility loci, which were previously identified in
European and/or Chinese populations, could be directly replicated in Korean women. Furthermore, this study
provides strong evidence implicating rs13393577 at 2q34 as a new risk variant for breast cancer.
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Introduction
Breast cancer, one of the most common malignancies
among women worldwide, is a complex polygenic dis-
ease in which genetic factors play a significant role in
the disease etiology [1,2]. So far, genome-wide associa-
tion studies (GWASs) have reported over 40 common
low-penetrance variants in 25 loci that are associated
with the breast cancer risk reported in the National
Human Genome Research Institute catalog [3]. The
most strongly and consistently associated single-nucleo-
tide polymorphisms (SNPs) reside in intron 2 of the
receptor tyrosine kinase FGFR2 (rs2981582) at 10q26.13
and near the 5’ end of the TOX3 gene at 16q12.1
(rs3803662) [4-9]. With the exception of three studies
conducted among Asian women [10-12], all other pre-
viously published GWASs have been conducted primar-
ily in women of European descent. Several studies,
including our study, have investigated previously identi-
fied loci in European populations in other ethnic groups
and validated the initial findings [13,14]. However,
newly discovered loci initially identified in women of
European descent tend to be weakly associated with
breast cancer in women of Asian descent [10,11] or
could not be confirmed in Asians because of the differ-
ence in linkage disequilibrium (LD) patterns between
ethnic populations, suggesting that additional genetic
variants for Asian women remain to be discovered.
In this study, we conducted a three-stage GWAS to
identify common breast cancer susceptibility loci and to
validate the previously reported loci by using Affymetrix
Genome-Wide Human SNP Array 6.0 (Affymetrix, Inc.,
Santa Clara, CA, USA) with 2,273 patients with breast
cancer from the Seoul Breast Cancer Study (SeBCS) and
2,052 healthy controls from a large urban cohort, the
Korea Genome Epidemiology Study (KoGES), as stage I.
By analyzing data from two replication stages that con-
sisted of 4,049 cases and 3,845 controls, we found
strong evidence for a new genetic variant that may be
associated with breast cancer risk among Asian women.
Materials and methods
Study population
A genome-wide association scan (stage I) was conducted
with 2,385 patients with breast cancer from the SeBCS
and 2,392 healthy controls from a large urban cohort
that is participating in the KoGES (Supplementary
methods in Additional file 1). For stage II, 2,052 cases
were selected among the patients who were the partici-
pants in SeBCS but not included in stage I and 2,169
controls from another cohort recruited from two small
cities with both urban and rural areas as part of KoGES.
For stage III, 1,997 cases were selected from two inde-
pendent breast cancer studies - the Korean Hereditary
Breast Cancer (KOHBRA) study (n = 1,289) and the
Yonsei Breast Cancer Study (n = 708) - and 1,676 con-
trols were selected from health examinees from rural
populations to study the risk factors for chronic dis-
eases. Detailed descriptions of these participants are
provided in Supplementary methods in Additional file 1,
and descriptive statistics of the study subjects are shown
in Table S2 of Additional file 2. The study protocols
were approved by the institutional review boards of
Seoul National University Hospital (institutional review
board # H-0503-144-004) and each collaborating insti-
tute (Description of study participants in Additional file
1). Informed consent was obtained from all participants.
Genotyping
A GWAS (stage I) was performed by a single platform
by using the Affymetrix Genome-Wide Human SNP
Array 6.0 chip (Affymetrix, Inc.). In total, 4,777 samples
were genotyped by using 500 ng of genomic DNA from
peripheral blood. The Birdseed V2 algorithm was used
to call the genotypes [15].
In total, 30 quality control (QC) samples were geno-
typed by using Affymetrix SNP Array 6.0. The average
concordance rate between the QC samples was 99.8%.
For internal validation of the Affymetrix SNP Array 6.0
platform, 12 SNPs were genotyped for all subjects by
SNPstream UHT (12-plex, SNP-IT assay, Orchid Bios-
ciences, Princeton, NJ). Samples of subjects that had a
genotype call rate of below 95%, a high heterozygosity
rate, or an incorrectly imputed gender were excluded.
Calculated genome-wide average identity by state (IBS)
between each pair of individuals was used to identify
individuals who appeared to be in relationships with
first-degree relatives or in relationships with more dis-
tant relatives whose clusters were tightly linked to the
first-degree relatives. Pairwise IBS between individuals
was calculated by using a subset of pruned markers
(74,965 SNPs) that are in approximate linkage equili-
brium. IBS analysis was performed by using the PLINK
software package. Multidimensional scaling analyses
based on pairwise IBS showed that, apart from some
outliers, all subjects clustered closely with HapMap
Asians (Figure S2 of Additional file 3). Subjects with a
cancer history and patients with diagnosed benign breast
cancer were subsequently excluded. Finally, 4,325 indivi-
duals remained in the association analyses (Table S1 of
Additional file 2).
To ensure quality data for SNPs, SNPs were excluded
if they met any of the following QC criteria: (a) devia-
tion from the Hardy-Weinberg equilibrium P value of
less than 10-6, (b) a genotype call rate of less than 95%,
(c) a minor allele frequency (MAF) of less than 1%, (d)
a poor cluster plot, (e) filtering out differential
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missingness between cases and controls (P < 10-4), and
(f) multiple positioning or mitochondrial SNPs or both.
In total, 555,525 Affymetrix SNP Array 6.0 SNPs were
used for the final association analyses (Table S1 of Addi-
tional file 2).
Genotyping for stages II and III was performed by
using the 5’ exonucleaseassay (TaqMan) employing the
ABI Prism 7900HT Sequence Detection System (Applied
Biosystems, Foster City, CA) in accordance with the
instructions of the manufacturer. Primers and probes
were supplied directly by Applied Biosystems (Foster
City, CA, USA) as Assays-By-Design. For QC, about
2.2% of the samples were genotyped repeatedly. Only
those SNPs that satisfied a concordance rate of greater
than 99% in duplicates and a genotype success rate of
greater than 99% were included in the subsequent repli-
cation phases.
Single-nucleotide polymorphism selection for validation
study using stage I
We selected the SNPs if they were implicated in pre-
vious GWASs and reported from the National Human
Genome Research Institute catalog [16]. We included
SNPs only if they had an assigned reference allele, a
defined MAF, and an estimated odds ratio (OR) or a
beta-coefficient and a 95% confidence interval (CI). For
the SNPs that were not genotyped by using Affymetrix
SNP Array 6.0 or successfully imputed (imputation QC
r2 was less than 0.3), we selected the best tagging SNPs
on the basis of the LD metrics (r2 and D’). Thus, we
selected rs10736303 for the SNPs at 10q21.13
(rs1219648, rs2981572, rs2981585, and rs2981579) and
rs10483813 for 14q24.1/RAD51L1 rs999737. We did not
include the SNP rs614367 at 11q13.3/MYEOV, CCND1,
ORAOV1, FGF19, FGF4, FGF3 since the MAF of
rs614367 is very low in this study (MAF = 0.002) [9].
Single-nucleotide polymorphism selection for replication
in stage II
After stage I, SNPs for replication were selected on the
basis of the following criteria among the 555,525 SNPs
that were directly genotyped and that had passed the
QC procedure: SNPs (a) with an MAF of more than
5% for either cases or controls, (b) with very clear gen-
otyping clusters, (c) with a Ptrend of per-allele OR of
not more than 5 × 10-4, and (d) not in strong LD (r2 <
0.5) with any of the GWAS-identified risk variants.
Additionally, to select the SNPs resided in SNP cluster
we selected the loci within which at least two SNPs
had a Ptrend of per-allele OR of not more than 5 × 10
-
3. When multiple SNPs showed LD within 100 kb (r2 >
0.2), the SNP with the lowest Ptrend was selected for
replication.
Single-nucleotide polymorphism imputation
To infer the genotype of SNPs that were not observed in
the Affymetrix Genome-Wide Human SNP Array 6.0
used in the present study, SNP imputation was carried
out by using the hidden Markov model as implemented
in MACH 1.0 [17,18]. Imputation was based on 555,525
autosomal SNPs that were genotyped in stage I and that
had passed the QC procedure, and the phased CHB +
JPT data from HapMap Phase II (release 22) were used
as the reference panel, which consisted of over 2.4 mil-
lion SNPs. In total, 2,210,823 SNPs showed an imputa-
tion quality score (r2) of at least 0.30. The average r2 of
SNPs not found on the array but included in the valida-
tion study (15 SNPs in Table 1) is 0.97.
Bioinformatics
The LD metrics (r2 and D’) between SNPs were calcu-
lated by using Haploview version 4.2 software (White-
head Institute, Cambridge, MA, USA) based on release
27, NCBI Build 36. Regional plots were drawn by using
LocusZoom standalone version 1.1 [19] based on Hap-
Map Phase II JPT+CHB for all SNPs in Figure S3 of
Additional file 3 except for rs10736303, which was
based on 1000 Genome August 2009 JTP+CHB.
Statistical analyses
Association on breast cancer risk was estimated by ORs
and 95% CIs while assuming an additive model by logis-
tic regression analysis adjusted for age. GWAS stage
(stage 1) analyses were conducted primarily by using
PLINK program version 1.06 [20] for directly genotyped
SNPs, and the MACH2dat program [17,18] was used for
imputed SNPs. For the comparison of the observed and
expected distribution of test statistics, quantile-quantile
analysis of 2-degrees-of-freedom logistic regression sta-
tistics was applied. The genomic inflation factor lamda
(l) was calculated as 1.043, suggesting that the popula-
tion substructure, if any, should not have a substantial
effect on result (Figure S1 of Additional file 3).
To control the risk of false discoveries, the multiple-
comparison-adjusted P values for stage II, stage III, and
combined analysis were calculated by the Benjamini-
Hochberg false discovery rate method [21]. Cochran’s Q
statistic to test for heterogeneity and the I2 statistic to
quantify the proportion of the total variation due to het-
erogeneity across all stages were calculated. Combined
statistics were estimated from meta-analysis while
assuming a fixed-effects model since there was no evi-
dence of heterogeneity. To assess the relationship
according to estrogen receptor (ER) or progesterone
receptor (PR) status or both, ORs and 95% CIs were
estimated after stratification by hormone receptor status.
Case-only P value was used to test for heterogeneity and
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Table 1 Association of previously identified loci with breast cancer risk in 2,257 cases and 2,052 controls in the Seoul
Breast Cancer Study
Region/Reported gene
(s)
SNP Loci evaluated in this study Loci reported in genome-wide association
studies
Risk
allele
RAF OR (95%
CI)a
P Genotyping Risk
allele
RAF OR (95%
CI)
P Reference
1p11.2/NOTCH2, FCGR1B rs11249433 C 0.04 1.11 (0.88-
1.40)
3.8 ×
10-1
Imputed C 0.39 1.16 (1.09-
1.24)
7 × 10-
10
[8]
2q35/Intergenic rs13387042 A 0.10 1.11 (0.96-
1.28)
1.6 ×
10-1
Imputed A 0.50 1.2 (1.14-
1.26)
1 × 10-
13
[6]
3p24.1/SLC4A7 rs4973768 T 0.22 1.09 (0.98-
1.21)
1.2 ×
10-1
Imputed T 0.47 1.16 (1.10-
1.24)
6 × 10-
7
[9]
5q11.2/MAP3K1 rs16886165 G 0.35 1.14 (1.04-
1.25)
6.5 ×
10-3
Imputed G 0.15 1.23 (1.12-
1.35)
5 × 10-
7
[8]
rs889312 C 0.55 1.16 (1.06-
1.27)
8.5 ×
10-4
Imputed C 0.28 1.13 (1.10-
1.16)
7 × 10-
20
[5]
5p12/MRPS30 rs7716600 A 0.48 1.13 (1.03-
1.23)
6.9 ×
10-3
Imputed A 0.23 1.24 (1.14-
1.34)
7 × 10-
7
[34]
rs4415084 T 0.56 1.09 (0.99-
1.19)
7.8 ×
10-2
Imputed T 0.42 1.17 (1.11-
1.22)
8 × 10-
11
[24]
5p15.2/ROPN1L rs1092913 G 0.30 1.11 (1.01-
1.22)
2.8 ×
10-2
Imputed T 0.13 1.45 (1.24-
1.69)
2 × 10-
6
[35]
6q22.33/ECHDC1, RNF146 rs2180341 G 0.27 1.03 (0.93-
1.13)
6.0 ×
10-1
Typed G 0.21 1.41 (1.25-
1.59)
3 × 10-
8
[36]
6q25.1/ESR1, C6orf97 rs3734805 C 0.33 1.20 (1.09-
1.33)
1.8 ×
10-4
Imputed C 0.08 1.19 (1.11-
1.27)
1 × 10-
7
[24]
rs2046210 A 0.35 1.29 (1.18-
1.41)
5.8 ×
10-8
Typed A 0.37 1.29 (1.21-
1.37)
2 × 10-
15
[10]
7q32.3/NR rs2048672 C 0.49 1.05 (0.97-
1.15)
2.3 ×
10-1
Typed C 0.45 1.11 (1.05-
1.17)
6 × 10-
6
[12]
8q24.21/Intergenic rs13281615 C 0.57 1.04 (0.95-
1.14)
3.8 ×
10-1
Imputed C 0.40 1.08 (1.05-
1.11)
5 × 10-
12
[5]
rs1562430 T 0.87 1.16 (1.01-
1.33)
3.0 ×
10-2
Imputed T 0.58 1.17 (1.10-
1.25)
6 × 10-
7
[9]
9p21.3/CDKN2A, CDKN2B rs1011970 T 0.07 1.00 (0.84-
1.19)
9.9 ×
10-1
Imputed T 0.17 1.09 (1.04-
1.14)
3 × 10-
8
[9]
9q31.2/KLF4, RAD23B,
ACTL7A
rs865686 T 0.93 1.02 (0.86-
1.21)
8.1 ×
10-1
Imputed T 0.61 1.12 (1.09-
1.18)
2 × 10-
10
[24]
10p15.1/ANKRD16,
FBXO18
rs2380205 C 0.91 1.11 (0.95-
1.29)
1.8 ×
10-1
Typed C 0.57 1.06 (1.02-
1.10)
5 × 10-
7
[9]
10q21.2/ZNF365 rs10995190 G 0.98 1.02 (0.76-
1.38)
8.9 ×
10-1
Imputed G 0.85 1.16 (1.10-
1.22)
5 × 10-
15
[9]
rs10822013 T 0.47 1.06 (0.97-
1.15)
2.1 ×
10-1
Typed T 0.47 1.12 (1.06-
1.18)
6 × 10-
9
[12]
10q22.3/ZMIZ1 rs704010 A 0.29 1.08 (0.98-
1.19)
1.2 ×
10-1
Typed A 0.39 1.07 (1.03-
1.11)
4 × 10-
9
[9]
10q26.13/FGFR2 rs10510102 G 0.18 1.01 (0.90-
1.13)
8.4 ×
10-1
Typed G 0.17 1.12 (1.07-
1.17)
2 × 10-
6
[24]
rs10736303b G 0.53 1.17 (1.07-
1.28)
4.4 ×
10-4
Typed T 0.41 1.17 (1.07-
1.27)
2 × 10-
10
[8]
11p15.5/LSP1 rs3817198 C 0.16 1.00 (0.89-
1.13)
9.5 ×
10-1
Typed C 0.30 1.07 (1.04-
1.11)
3 × 10-
9
[5]
14q24.1/RAD51L1 rs10483813c T 0.97 1.21 (0.93-
1.56)
1.6 ×
10-1
Imputed C 0.76 1.06 (1.01-
1.14)
2 × 10-
7
[8]
16q12.1/TOX3 rs4784227 T 0.29 1.27 (1.15-
1.40)
1.5 ×
10-6
Typed T 0.24 1.24 (1.20-
1.29)
1 × 10-
28
[11]
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was estimated by using a polytomous logistic regression
model with receptor status as the outcome variables.
The statistical power of detecting the ORs reported in
previous GWASs was calculated by using Quanto ver-
sion 1.2.4. All other analyses other than GWAS stage
were done by using SAS version 9.2 (SAS Institute Inc.,
Cary, NC, USA) and STATA version 11.2 (StataCorp
LP, College Station, TX, USA).
Results
Validation of previously identified breast cancer
susceptibility loci in Korean women
We found that multiple genomic locations were poten-
tially associated with the risk of breast cancer (Figure
1). Table 1 presents the test of associations between
the previously reported loci and breast cancer risk in
2,257 cases and 2,052 controls. Among the 27 SNPs
reported in published GWASs, 10 SNPs located in
seven loci showed significant associations with breast
cancer risk (Ptrend < 0.05). Plots of regional LD and
strength of association by chromosomal position for
these seven loci of interest are shown in Figure S3 of
Additional file 3.
The strongest and most significant association was
observed in 6q25.1/ESR1 rs2046210 (OR = 1.29; 95% CI
= 1.18 to 1.41; Ptrend = 5.84 × 10
-8) followed by
16q12.1/TOX3 rs4784227 (OR = 1.27; 95% CI = 1.15 to
1.40; Ptrend = 1.51 × 10
-6), and these values are slightly
similar to the magnitude and direction of previous
reports. The SNPs 6q25.1/ESR1 rs3734802 and 16q12.1/
TOX3 rs3803662, which had a moderate LD with
rs2046210 (r2 = 0.317 in CHB+JPT) and rs4784227 (r2 =
0.139 in CHB+JPT), respectively, were also significantly
associated with breast cancer risk (OR = 1.20; 95% CI =
1.09 to 1.33; Ptrend = 1.8 × 10
-4 and OR = 1.24; 95% CI
= 1.14 to 1.36; Ptrend = 2.41 × 10
-6, respectively).
Although allele frequencies of 5q11.2/MAP3K1 rs889312
(like 16q12.1/TOX3 rs3803662) were substantially differ-
ent between Europeans and Koreans, the rs889312 C
allele was also significantly associated with increased
risk of breast cancer (OR = 1.16; 95% CI = 1.06 to 1.27;
Ptrend = 8.49 × 10
-4). The 10q26.13/FGFR2 rs10736303
(proxy of rs2981579), 5p15.2/ROPN1L rs1092913, 5q12/
MRPS30 rs7716600, and 8q24.21 rs1562430 were also
confirmed to be associated with breast cancer risk,
although the magnitude of the last three SNPs was
Figure 1 Manhattan plot for 555,525 genotyped single-nucleotide polymorphisms in 2,273 cases and 2,052 controls.
Table 1 Association of previously identified loci with breast cancer risk in 2,257 cases and 2,052 controls in the Seoul
Breast Cancer Study (Continued)
rs3803662 T 0.64 1.24 (1.14-
1.36)
2.4 ×
10-6
Typed T 0.27 1.28 (1.21-
1.35)
6 × 10-
19
[5]
19q13.41/ZNF577 rs10411161 C 0.72 1.01 (0.92-
1.11)
8.6 ×
10-1
Typed T 0.13 1.42 (1.22-
1.65)
7 × 10-
6
[35]
The average call rate was 99.8% (range of 99.4% to 100%) for typed single-nucleotide polymorphisms (SNPs), and the average of imputation quality score from
MACH (r2) was 0.97 (range of 0.95 to 1.00). aPer-allele odds ratio (OR) adjusted for age; bproxy SNP of rs2981579 (r2 = 0.48 in CHB+JPT; r2 = 0.74 in CEU); cproxy
SNP of rs999737 (r2 = 0.50 in CHB+JPT; r2 = 0.98 in CEU). CEU, CEPH Utah residents with ancestry from Northern and Western Europe; CHB+JPT, Han Chinese
from Beijing + Japanese from Tokyo; CI, confidence interval; RAF, risk allele frequency.
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smaller than that of previous reports. However, 14q24.1/
RAD51L1 rs10483813 (proxy of rs999737) showed no
significant association with an OR of 1.21. Additionally,
none of the remaining 17 SNPs was replicated in our
study (P > 0.05), and the effect sizes were estimated to
be less than 1.10, which is lower than that of the esti-
mated ones in women of European descent.
We further assessed these associations according to
ER and PR status (Table S3 of Additional file 2). The
5q12/MRPS30 rs7716600 and rs4415084 exhibited a
stronger association with ER+ than with ER- tumors
(Pheterogeneity = 0.02 and Pheterogeneity = 0.05, respectively).
Although no overall associations were found for 2q35
rs13387042 and 10p15.1/ANKRD16, FBXO18 rs2380205,
stratified analysis revealed a statistically significant asso-
ciation with ER+ (Ptrend = 0.03 and Ptrend = 0.04) or PR
+
(Ptrend = 0.05 and Ptrend = 0.05) tumors but not with
ER- or PR- tumors. The test for heterogeneity was sig-
nificant only for 10p15.1/ANKRD16, FBXO18 rs2380205
(Pheterogeneity ER+ vs. ER- = 0.030 and Pheterogeneity PR+ vs.
PR- = 0.040). Additionally, two SNPs at 6q25.1/ESR1
(rs2046210 and rs3784805) exhibited a stronger associa-
tion with ER- than with ER+ tumors, although the differ-
ences were not statistically significant. There were no
differences in associations by ER or PR status for the
remaining SNPs.
Analysis of 2q34 rs13393577 and breast cancer risk
To search for additional independent genetic risk var-
iants in Korean women, we selected the most suggestive
17 SNPs from stage I and genotyped in an independent
set of 2,052 cases and 2,169 controls (stage II). Among
the 17 SNPs evaluated in stage II, only one SNP,
rs13393577 at 2q34, was significantly associated with
breast cancer risk. The estimated ORs for rs13393577
were as follows: ORheterozygote = 1.39 (95% CI = 1.16 to
1.67; P = 2.05 × 10-5), ORhomozygote = 5.57 (95% CI =
2.26 to 13.7; P = 4.10 × 10-3), and ORper-allele = 1.51
(95% CI = 1.29 to 1.78; Ptrend = 1.1 × 10
-5). SNP
rs13393577 and three more SNPs (3q26.32 rs3806685,
6q25.1 rs9498283, and 17q24.3 rs11077488) showing
marginally significant associations in stage II (Ptrend <
0.10) were further evaluated in stage III, which included
1,997 cases and 1,676 controls. Again, rs13393577
showed a significant association with breast cancer risk
(Table 2). The Ptrend reached 8.8 × 10
-14 in the com-
bined analysis (Figure 2). The SNP rs3806685 at 3q26.32
was also associated with breast cancer risk with an
ORper-allele of 1.18 (95% CI = 1.04 to 1.34; Ptrend = 1.8 ×
10-2) in stage III; however, the combined OR was not
significant (Ptrend = 5.9 × 10
-1). The other two SNPs
showed no significant association in stage III or in the
combined analysis (P > 0.05). The test for heterogeneity
suggested no difference in the genetic effects across ER
or PR status for rs13393577 (data not shown). To cap-
ture additional signals for rs13393577, we investigated
the SNPs nearby rs13393577 (Figure 3). Among the
directly genotyped SNPs, two SNPs are in strong LD (r2
> 0.8) with rs13393577, and the smallest P values were
1.2 × 10-3 for rs6756468 (r2 = 1.00) and 2.6 × 10-2 for
rs16848753 (r2 = 0.81). SNP rs6756468 is in tight LD
with rs13393577 located in the LD block containing the
mir-548f-2 gene. Several imputed SNPs in high LD with
rs13393577 were nominally associated with breast can-
cer risk (P < 0.05) (Table S5 of Additional file 2).
Discussion
In the present study, we conducted a three-stage GWAS
in Korean women (6,322 cases and 5,897 controls). We
not only confirmed previously identified loci in Eur-
opeans or Chinese populations or both but also found
rs13393577 at 2q34/ERBB4 as a new breast cancer sus-
ceptibility variant in Korean women.
In the validation study, we evaluated whether 27 SNPs
in the 20 GWAS-identified loci were also relevant in
our population using stage I and identified that 10 SNPs
at seven loci were significantly associated with breast
cancer risk. As anticipated, the strongest and the most
significant results were observed in rs2046210 at 6q25.1/
ESR1 and rs4784227 at 16q12.1/TOX3, and these results
are slightly similar to those of the magnitude and direc-
tion of previous reports conducted in a Chinese popula-
tion [10,11]. For the SNPs rs2048671 at 7q32.3/NR and
rs10822013 at 10q21.2/ZNF365, which were also identi-
fied in Asians, we recently reported significant associa-
tions with breast cancer risk through multi-stage GWAS
with a cumulative sample size up to over 34,000 East
Asian subjects (OR per-allele = 1.10; 95% CI = 1.07 to
1.14; Ptrend = 5.87 × 10
-9 and OR = 1.08; 95% CI = 1.04
to 1.11; Ptrend = 6.21 × 10
-6) [12]. However, the associa-
tions of these SNPs were not significant in this study,
possibly because of its limited power.
Among the remaining 23 SNPs that were initially
identified in Europeans, eight SNPs - rs10736303
(10q26.13/FGFR2, proxy of rs2981579), rs3803662
(16q12.1/TOX3), rs7716600 (5p12/MRPS30), rs16886165
and rs889312 (5q11.2/MAP3K1), rs3734805 (6q25.1/
ESR1), and rs1562430 (8q24.21) - showed significant
associations in the same direction except for rs1092913
(5p15.2/ROPN1L) with the G allele as the risk allele.
The effect sizes of the confirmed variants were similar
to or smaller than those of the initially identified ones.
This phenomenon has been frequently observed in vali-
dation studies using ethnic populations different from
the population used for the initial findings [22,23].
In addition, we could not evaluate the SNPs
(rs1219648, rs2981572, rs2981585, and rs2981579) pre-
viously identified within intron 2 of FGFR2 at 10q21.13,
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Table 2 Results of four single-nucleotide polymorphisms and breast cancer risk identified in genome-wide association
studies (stage I) and replication stages (stages II and III)
SNPa Genomic
locationb
Stage Number
of cases
Number of
controls
MAF in
cases
MAF in
controls
HWE
P
Heterozygote
OR (95% CI)a
Homozygote
OR (95% CI)a
Per-
allele
OR
(95%
CI)c
Ptrend
d
rs13393577 213,005,108 I 2,269 1,992 0.066 0.039 0.25 1.72 (1.38-2.13) 2.25 (0.79-6.42) 1.68
(1.38-
2.06)
4.8 ×
10-7
(C/T) (2q34) II 2,037 2,166 0.096 0.066 0.22 1.39 (1.16-1.67) 5.57 (2.26-13.7) 1.51
(1.29-
1.78)
1.1 ×
10-5
III 1,952 1,644 0.061 0.047 0.83 1.35 (1.07-1.70) 2.70 (0.81-9.03) 1.38
(1.11-
1.71)
1.3 ×
10-2
Combined 6,258 5,802 0.074 0.051 1.47 (1.28-1.70) 3.49 (1.93-6.33) 1.53
(1.37-
1.70)
8.8 ×
10-14
rs9498283 149,646,875 I 2,266 2,051 0.451 0.500 0.08 0.79 (0.68-0.91) 0.67 (0.56-0.79) 0.81
(0.75-
0.89)
5.3 ×
10-6
(A/G) (6q25.1) II 2,049 2,145 0.449 0.470 0.05 0.97 (0.84-1.12) 0.85 (0.71-1.01) 0.92
(0.85-
1.01)
6.8 ×
10-1
III 1,988 1,657 0.453 0.478 0.28 1.02 (0.87-1.19) 0.85 (0.70-1.03) 0.93
(0.84-
1.02)
1.6 ×
10-1
Combined 6,303 5,853 0.451 0.451 0.92 (0.79-1.07) 0.78 (0.66-0.92) 0.89
(0.82-
0.96)
9.6 ×
10-3
rs11077488 65,801,677 I 2,273 2,052 0.150 0.185 0.58 0.77 (0.67-0.89) 0.60 (0.41-0.86) 0.77
(0.69-
0.87)
1.2 ×
10-5
(C/T) (17q24.3) II 2,046 2,141 0.155 0.171 0.93 0.88 (0.76-1.01) 0.87 (0.60-1.27) 0.90
(0.80-
1.01)
9.7 ×
10-1
III 1,984 1,669 0.164 0.163 0.90 1.02 (0.87-1.18) 0.98 (0.65-1.49) 1.01
(0.89-
1.15)
1.1 ×
10-1
Combined 6,303 5,862 0.156 0.174 0.88 (0.76-1.02) 0.79 (0.59-1.07) 0.89
(0.76-
1.03)
1.6 ×
10-1
rs3806685 180,522,445 I 2,262 2,051 0.156 0.189 0.95 0.90 (0.79-1.03) 0.25 (0.15-0.41) 0.78
(0.69-
0.88)
3.4 ×
10-5
(A/G) (3q26.32) II 2,040 2,163 0.169 0.177 0.11 0.84 (0.73-0.97) 1.04 (0.72-1.52) 0.90
(0.80-
1.01)
9.7 ×
10-1
III 1,971 1,657 0.189 0.162 0.93 1.22 (1.05-1.42) 1.24 (0.83-1.83) 1.18
(1.04-
1.34)
1.8 ×
10-2
Combined 6,273 5,871 0.171 0.177 0.97 (0.78-1.21) 0.69 (0.28-1.70) 0.94
(0.74-
1.18)
5.9 ×
10-1
aMajor/Minor allele; blocation is based on NCBI Build 36; codds ratio (OR) adjusted for age; dPtrend values of stage II, stage III, and combined analysis were
adjusted for the multiple comparisons by using false discovery rate. CI, confidence interval; GWAS, genome-wide association study; HWE, Hardy-Weinberg
equilibrium; MAF, minor allele frequency; SNP, single-nucleotide polymorphism.
Kim et al. Breast Cancer Research 2012, 14:R56
http://breast-cancer-research.com/content/14/2/R56
Page 7 of 12
because they were not genotyped or successfully
imputed (imputation QC r2 < 0.3). Thus, we selected
rs10736303 as the best tagging SNP capturing 10q26.13/
FGFR2 since it is in high LD with the reported SNPs
with pairwise r2 values of 0.67 for rs2981579 (r2 = 0.48
in CHB+JTP; r2 = 0.74 in CEU), 0.57 for rs2981575 (r2
= 0.36 in CHB+JPT; r2 = 0.72 in CEU), and 0.53 for
rs1219648 (r2 = 0.29 in CHB+JPT; r2 = 0.72 in CEU) on
the basis of our data. Furthermore, the rs10736393 is
located at intron 2 of FGFR2 within the sequences con-
served across all placental mammals and suggested to
be a functional variant to regulate FGFR expression by
generating a putative ER-binding site [5]. In the present
study, the rs10736393 G allele was significantly asso-
ciated with increased breast cancer risk with an effect
size of rs2981579 that was the same as in a previous
report [8]. However, the recently added SNP,
rs10510102, located in the 300-kb telomeric region of
intron 2 of FGFR2 but not with a genome-wide signifi-
cance level (P = 1.6 × 10-6), was not replicated in the
present study [24].
Subgroup analysis revealed that some of the validated
associations differed by ER or PR status. Recent studies
showed stronger associations with ER+ than with ER-
tumors for several loci - rs13387042(2q35), rs4973768
(3p24), rs889312 (5q11.2/MAP3K1), rs7716600 (5q12/
MRP30), rs13281615 (8q24), rs1219648 and rs2981582
(10q26.13/FGFR2), and rs3803662 (16q12) - and with
PR+ than with PR- tumors for rs2981582 (10q26.13/
FGFR2) [6,25,26]. Among these loci, rs13387042 (2q35),
rs7716600, and rs4415084 (5q12/MRP30) showed signif-
icantly different associations by ER status, and
rs4973768 (3p24) also showed a stronger association
with ER+ tumors, although the test for heterogeneity
was not significant. The association of rs2380205
(10p15.1/ANKRD16, FBXO18) with breast cancer risk
was also stronger for ER+ or PR+ tumors than with
negative tumors, and this heterogeneity in association
remains to be evaluated in other populations.
The stronger association of rs2046210 at 6q25.1/ESR1
with ER- than with ER+ tumors has been well documen-
ted [10]. In the present study, we could also observe this
heterogeneity for rs2046210 and its nearby SNP
rs3784805, although the differences were not statistically
significant. Direct replication in some of the loci show-
ing significant differences in associations according to
ER or PR status provides further support for the hypoth-
esis that intrinsic subtypes of breast cancer should have
different etiologic pathways; thus, the polygenic compo-
nent of these subtypes of breast cancer should be differ-
ent [27].
There are several potential reasons for the failure of
validation for previously identified loci in women of
European descent. First, several risk variants could
escape detection because of the limited statistical power
caused by either low allele frequency or a very small
effect size of the initial findings. There are several SNPs
of which the allele frequencies in Koreans are substan-
tially lower than in Europeans: SNP rs11249433 at
1p11.2/NOTCH2, FCGR1B (4% versus 39%), rs1011970
Figure 2 Forest plot. Result of pooled analysis of rs13393577 on the basis of estimated per-allele odds ratio from each stage. CI, confidence
interval; ES, effect size.
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at 9p21.3/CDKN2A, CDKN2B (7% versus 17%),
rs865686 at 9q31.2/KLF4, RAD23B, ACTL7A (7% versus
24%), rs10995190 at 10q21.2/ZNF365 (2% versus 15%),
and rs10483813, proxy of rs999737, at 14q24.1/RAD51L
(3% versus 24%). Thus, we have only 8% to 30% of the
statistical power to detect the reported effect sizes of
1.06 to 1.16 for these SNPs with the current sample
size. We could not exclude the possibility that the effect
size of the original reports could be represented as exag-
gerated ORs caused by ‘winner’s curse’. Second, a differ-
ence in underlying genomic structure between
ethnicities could produce the bias to cover SNPs tagging
the causal variants, although the reported SNPs could
work effectively in women of European descent.
Figure 3 Regional association plot of the 2q34 (rs13393577) locus. The results of association signals (-log P) are shown for directly
genotyped (diamonds) and imputed (triangle) single-nucleotide polymorphisms (SNPs) distributed in a genomic region 500 kb to either side of
rs1339577. Red reflects the linkage disequilibrium (r2) with the top SNP, and increasing red hue is associated with increasing r2. The blue bars
show the recombination rate based on HapMap phase II release 22 JPT and CHB populations. The bottom panels illustrate the locations of
known genes. The genomic position is based on the UCSC (University of California at Santa Cruz) Genome Browser assembly, March 2010. CHB,
Han Chinese from Beijing; JPT, Japanese from Tokyo.
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Another possibility is that some of the variants evalu-
ated may not be strongly associated with breast cancer
risk in Asian women such as shown in the null associa-
tion of rs2180341 (6q22.33). For rs3180341, we had a
statistical power of 80% to detect an OR as small as
1.15; furthermore, the lack of an association has been
shown in a study conducted in a Chinese population
[13]. Moreover, the risk profiles of genetic variants
could be manifested differently in different ethnic popu-
lations, assuming that the relative contribution of the
risk variants to carcinogenic pathways of breast cancer
varies between different populations. Finally, the interac-
tions of environmental exposures, lifestyle, or other
effect modifiers and even the difference in breast cancer
prevalence could have an effect on the penetrance of
these alleles.
The ERBB4, harboring rs13393577 in the first intron
at 2q34, is a member of the epidermal growth factor
(EGF/ERBB) family of receptor tyrosine kinases, which
are key activators of signaling pathways involved in cell
division, migration, adhesion, differentiation, and apop-
tosis [28]. It is reported that ERBB4 is frequently over-
expressed in breast cancer, and the expression of
transcripts encoding the cleavable ERBB4 isoforms was
associated with ER expression and a high histological
grade of differentiation [29]. Rokavec and colleagues
[30] identified the presence of five germ-line variants in
the ERBB4 5’-untranslated region and reported that one
of these variants (ERBB4 -782T > G) was associated
with breast cancer risk from the different promoter
activity according to the different allele. However,
rs13393577 is not in LD with ERBB4 -782T > G; thus,
the potential influence of rs13393577 is unlikely to be
mediated through this previously reported variant.
We conducted an in silico functional analysis to assess
the potential biological function of rs13393577. The
rs13393577 C allele had no predicted binding site,
whereas several transcription factors were predicted to
bind the rs13393577 T allele implementing six high-
scoring binding sites (maximum score = 92.7 points;
minimum score = 85.9 points) [31]. In agreement with
this, FASTSNP scored rs13393577 as 1-2 (intronic
enhancer) [32]. Additionally, Murabito and colleagues
[33] have shown that three SNPs in ERBB4 (rs905883,
rs7564590, and rs7558615) were associated with breast
cancer risk in a family-based GWAS that included 58
breast cancer cases, although no association was
attained with genome-wide significance level. Among
these variants, rs7564590 is in moderate LD with
rs13393577 (r2 = 0.44 in CHB+JPT and r2 = 0.25 in
CEU) whereas the other two SNPs (rs905883 and
rs755861515) are in very weak LD with rs13393577 (all
r2 < 0.02 in CHB+JPT and CEU). Thus, if both
rs13393577 and rs7564590 are not themselves
functional, they might be in high LD with the true cau-
sal variants. Additionally, we could not exclude the pos-
sibility that the strong association shown in rs13393577
is related to the function of the mir-548f-2 gene harbor-
ing SNP rs6956468, which is in tight LD with
rs13393577.
Conclusions
In summary, we have confirmed 10 SNPs in seven loci
of breast cancer risk which were initially identified in
European or Chinese populations or both and provided
additional evidence confirming the heterogeneity in the
risk of different tumor subtypes for common breast can-
cer susceptibility variants. Moreover, we identified
rs13393577 in ERBB4 located at 2q34 as a new breast
cancer susceptibility variant. Future studies, including
fine mapping, functional assay, and a replication study
with large sample sizes from diverse ethnic populations,
are needed to validate our results.
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